NCT00704782终止2 期
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 50
- 试验地点
- 4
- 主要终点
- To assess the safety of Dimebon in combination with donepezil (Aricept)
研究概览
简要总结
The purpose of this study is to assess the safety and efficacy of Dimebon in combination with donepezil (Aricept) in the treatment of Alzheimer's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Alzheimer's disease
- •On donepezil (Aricept)
- •Caregiver who cares for the patient at least 5 days per week
排除标准
- •Unstable medical illnesses or significant hepatic or renal disease
- •Other primary psychiatric or neurological disorders
研究组 & 干预措施
Dimebon
Experimental
20 mg by mouth 3 times a day
干预措施: dimebon (Drug)
结局指标
主要结局
To assess the safety of Dimebon in combination with donepezil (Aricept)
时间窗: week 6, 9, 12, 26 and every 13 weeks thereafter until study discontinuation
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of DextromethorphanAlzheimer DiseaseHuntington DiseaseNCT00788047Pfizer14
终止
3 期
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's DiseaseAlzheimer's DiseaseNCT00939783Pfizer649
已完成
2 期
ACVDL Treatment for Patients With Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT01481194Vejle Hospital35
终止
3 期
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's DiseaseAlzheimer's DiseaseNCT01066546Pfizer5
已完成
1 期
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsHuntington's DiseaseAlzheimer's DiseaseNCT00827034Pfizer14